Complex of an active μ-opioid receptor with a cyclic peptide agonist modeled from experimental constraints

Biochemistry

Volumn 43, Issue 50, 2004, Pages 15796-15810

  Fowler, Carol B ^a   Pogozheva, Irina D ^a   Lomize, Andrei L ^a   LeVine III, Harry ^b   Mosberg, Henry I ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; CHEMICAL BONDS; MUTAGENESIS; SUBSTITUTION REACTIONS; ZINC;

BINDING AFFINITY; SITE-DIRECTED MUTAGENESIS; TETRAPEPTIDES;

PROTEINS;

CYCLOPEPTIDE; MU OPIATE RECEPTOR; MUTANT PROTEIN; PROTEIN JOM6; RHODOPSIN; TETRAPEPTIDE; UNCLASSIFIED DRUG; ZINC;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DISULFIDE BOND; HYDROGEN BOND; MATHEMATICAL MODEL; METAL BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; RAT; SEQUENCE ALIGNMENT; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; BINDING SITES; CATTLE; CERCOPITHECUS AETHIOPS; COS CELLS; DNA MUTATIONAL ANALYSIS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PEPTIDES, CYCLIC; POINT MUTATION; PROTEIN CONFORMATION; RATS; RECEPTORS, OPIOID, MU; ZINC;

ANIMALIA;

EID: 10844246435     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi048413q     Document Type: Article

References (93)

1. Kieffer, B. L. (2000) Opioid receptors: from genes to mice, J. Pain 1 (Suppl. 3), 45-50.
2. Burford, N. T., Tolbert, L. M., and Sadee, W. (1998) Specific G protein activation and μ-opioid receptor internalization caused by morphine, DAMGO and endomorphin I, Eur. J. Pharmacol. 342, 123-126.
3. Quock, R. M., Burkey, T. H., Varga, E., Hosohata, Y., Hosohata, K., Cowell, S. M., Slate, C. A., Ehlert, F. J., Roeske, W. R., and Yamamura, H. I. (1999) The δ-opioid receptor: molecular pharmacology, signal transduction, and the determination of drug efficacy, Pharmacol. Rev. 51, 503-532.
4. Waldhoer, M., Bartlett, S. E., and Whistler, J. L. (2004) Opioid receptors, Annu. Rev. Biochem. 73, 953-990.
5. Ghanouni, P., Steenhuis, J. J., Farrens, D. L., and Kobilka, B. K. (2001) Agonist-induced conformational changes in the G-protein-coupling domain of the β2 adrenergic receptor, Proc. Natl. Acad. Sci. U.S.A. 98, 5997-6002.
6. Ghanouni, P., Gryczynski, Z., Steenhuis, J. J., Lee, T. W., Farrens, D. L., Lakowicz, J. R., and Kobilka, B. K. (2001) Functionally different agonists induce distinct conformations in the G protein coupling domain of the β2 adrenergic receptor, J. Biol. Chem. 276, 24433-24436.
7. Swaminath, G., Xiang, Y., Lee, T. W., Steenhuis, J., Parnot, C., and Kobilka, B. K. (2004) Sequential binding of agonists to the β2 adrenoceptor. Kinetic evidence for intermediate conformational states, J. Biol. Chem. 279, 686-691.
8. Ballesteros, J. A., and Weinstein, H. (1995) Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G-protein coupled receptors, Methods Neurosci. 25, 366-428.
9. Gershengorn, M. C., and Osman, R. (2001) Minireview: Insights into G protein-coupled receptor function using molecular models, Endocrinology 142, 2-10.
10. Stenkamp, R. E., Filipek, S., Driessen, C. A., Teller, D. C., and Palczewski, K. (2002) Crystal structure of rhodopsin: a template for cone visual pigments and other G protein-coupled receptors, Biochim. Biophys. Acta 1565, 168-182.
11. Filipek, S., Teller, D. C., Palczewski, K., and Stenkamp, R. (2003) The crystallographic model of rhodopsin and its use in studies of other G protein-coupled receptors, Annu. Rev. Biophys. Biomol. Struct. 32, 375-397.
12. Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N., and Bourne, P. E. (2000) The Protein Data Bank, Nucleic Acids Res. 28, 235-242.
13. Riek, R. P., Rigoutsos, I., Novotny, J., and Graham, R. M. (2001) Non-α-helical elements modulate polytopic membrane protein architecture, J. Mol. Biol. 306, 349-362.
14. Archer, E., Maigret, B., Escrieut, C., Pradayrol, L., and Fourmy, D. (2003) Rhodopsin crystal: new template yielding realistic models of G-protein-coupled receptors? Trends Pharmacol. Sci. 24, 36-40.
15. Fowler, C. B., Pogozheva, I. D., LeVine, H., III, and Mosberg, H. I. (2004) Refinement of a Homology Model of the μ-Opioid Receptor Using Distance Constraints from Intrinsic and Engineered Zinc-Binding Sites, Biochemistry 43, 8700-8710.
16. Okada, T., Ernst, O. P., Palczewski, K., and Hofmann, K. P. (2001) Activation of rhodopsin: new insights from structural and biochemical studies, Trends Biochem. Sci. 26, 318-324.
17. Hubbell, W. L., Altenbach, C., Hubbell, C. M., and Khorana, H. G. (2003) Rhodopsin structure, dynamics, and activation: a perspective from crystallography, site-directed spin labeling, sulfhydryl reactivity, and disulfide cross-linking, Adv. Protein Chem. 63, 243-290.
18. Gether, U. (2000) Uncovering molecular mechanisms involved in activation of G protein-coupled receptors, Endocr. Rev. 21, 90-113.
19. Meng, E. C., and Bourne, H. R. (2001) Receptor activation: what does the rhodopsin structure tell us? Trends Pharmacol. Sci. 22, 587-593.
20. Parnot, C., Miserey-Lenkei, S., Bardin, S., Corvol, P., and Clauser, E. (2002) Lessons from constitutively active mutants of G protein-coupled receptors, Trends Endocrinol. Metab. 13, 336-343.
21. Karnik, S. S., Gogonea, C., Patil, S., Saad, Y., and Takezako, T. (2003) Activation of G-protein-coupled receptors: a common molecular mechanism, Trends Endocrinol. Metab. 14, 431-437.
22. Farrens, D. L., Altenbach, C., Yang, K., Hubbell, W. L., and Khorana, H. G. (1996) Conformational changes in rhodopsin. Movement of helix f detected by site-specific chemical labeling and fluorescence spectroscopy, J. Biol. Chem. 274, 1683-1690.
23. Gether, U., Lin, S., Ghanouni, P., Ballesteros, J. A., Weinstein, H., and Kobilka, B. K. (1997) Agonists induce conformational changes in transmembrane domains III and VI of the β2 adrenoceptor, EMBO J. 16, 6737-6747.
24. Dunham, T. D., and Farrens, D. L. (1999) Conformational changes in rhodopsin. Movement of helix f detected by site-specific chemical labeling and fluorescence spectroscopy, J. Biol. Chem. 274, 1683-1690.
25. Han, M., Smith, S. O., and Sakmar, T. P. (1998) Constitutive activation of opsin by mutation of methionine 257 on transmembrane helix 6, Biochemistry 37, 8253-8261.
26. Cai, K., Klein-Seetharaman, J., Hwa, J., Hubbell, W. L., and Khorana, H. G. (1999) Structure and function in rhodopsin: effects of disulfide cross-links in the cytoplasmic face of rhodopsin on transducin activation and phosphorylation by rhodopsin kinase, Biochemistry 38, 12893-12898.
27. Janz, J. M., and Farrens, D. L. (2004) Rhodopsin activation exposes a key hydrophobic binding site for the transducin α-subunit C-terminus, J. Biol. Chem. 279, 29767-29773.
28. Lin, S. W., and Sakmar, T. P. (1996) Specific tryptophan UV-absorbance changes are probes of the transition of rhodopsin to its active state, Biochemistry 35, 11149-11159.
29. Altenbach, C., Klein-Seetharaman, J., Hwa, J., Khorana, H. G., and Hubbell, W. L. (1999) Structural features and light-dependent changes in the sequence 59-75 connecting helices I and II in rhodopsin: a site-directed spin-labeling study, Biochemistry 38, 7945-7949.
30. Altenbach, C., Cai, K., Klein-Seetharaman, J., Khorana, H. G., and Hubbell, W. L. (2001) Structure and function in rhodopsin: mapping light-dependent changes in distance between residue 65 in helix TM1 and residues in the sequence 306-319 at the cytoplasmic end of helix TM7 and in helix H8, Biochemistry 40, 15483-15492.
31. Altenbach, C., Klein-Seetharaman, J., Cai, K., Khorana, H. G., and Hubbell, W. L. (2001) Structure and function in rhodopsin: mapping light-dependent changes in distance between residue 316 in helix 8 and residues in the sequence 60-75, covering the cytoplasmic end of helices TM1 and TM2 and their connection loop CL1, Biochemistry 40, 15493-15500.
32. Ward, S. D., Hamdan, F. F., Bloodworth, L. M., and Wess, J. (2002) Conformational changes that occur during M3 muscarinic acetylcholine receptor activation probed by the use of an in situ disulfide cross-linking strategy, J. Biol. Chem. 277, 2247-2257.
33. 2+ on the β2 adrenergic receptor, J. Biol. Chem. 278, 352-356.
34. Elling, C. E., Thirstrup, K., Holst, B., and Schwartz, T. W. (1999) Conversion of agonist site to metal-ion chelator site in the β2-adrenergic receptor, Proc. Natl. Acad. Sci. U.S.A. 96, 12322-12327.
35. Holst, B., Elling, C. E., and Schwartz, T. W. (2000) Partial agonism through a zinc-ion switch constructed between transmembrane domains III and VII in the tachykinin NK(1) receptor, Mol. Pharmacol. 58, 263-270.
36. Lagerstrom, M. C., Klovins, J., Fredriksson, R., Fridmanis, D., Haitina, T., Ling, M. K., Berglund, M. M., and Schioth, H. B. (2003) High affinity agonistic metal ion binding sites within the melanocortin 4 receptor illustrate conformational change of transmembrane region 3, J. Biol. Chem. 278, 51521-51526.
37. Mosberg, H. I., Omnaas, J. R., Medzihradsky, F., and Smith, C. B. (1988) Cyclic, disulfide- and dithioether-containing opioid tetrapeptides: development of a ligand with high δ opioid receptor selectivity and affinity, Life Sci. 43, 1013-1020.
38. McFadyen, I. J., Sobczyk-Kojiro, K., Schaefer, M. J., Ho, J. C., Omnaas, J. R., Mosberg, H. I., and Traynor, J. R. (2000) Tetrapeptide derivatives of [D-Pen(2),D-Pen(5)]-enkephalin (DP-DPE) lacking an N-terminal tyrosine residue are agonists at the μ-opioid receptor, J. Pharmacol. Exp. Ther. 295, 960-966.
39. 1 replacements in the cyclic δ receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13), J. Med. Chem. 37, 4371-4383.
40. 3 replacements in the cyclic δ-receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13), J. Med. Chem. 37, 4384-4391.
41. Mosberg, H. I., Dua, R. K., Pogozheva, I. D., and Lomize, A. L. (1996) Development of a model for the δ opioid receptor pharmacophore: 4. Residue 3 dehydrophenyl-alanine analogs of Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13) confirm required gauche orientation of aromatic side chain, Biopolymers 39, 287-296.
42. 1H NMR data, J. Am. Chem. Soc. 116, 429-436.
43. Ho, J. C. (1997) Development of a model for the δ-opioid receptor pharmacophore, Ph.D. Thesis, University of Michigan, Ann Arbor, MI.
44. Mansour, A., Hoversten, M. T., Taylor, L. P., Watson, S. J., and Akil, H. (1995) The cloned μ, δ and κ receptors and their endogenous ligands: evidence for two opioid peptide recognition cores, Brain Res. 700, 89-98.
45. Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, Anal. Biochem. 72, 248-254.
46. 50) of an enzymatic reaction, Biochem. Pharmacol. 22, 3099-3108.
47. Güntert, P., and Wüthrich, K. (1991) Improved efficiency of protein structure calculations from NMR data using the program DIANA with redundant dihedral angle constraints, J. Biomol. NMR 1, 447-456.
48. Pogozheva, I. D., Lomize, A. L., and Mosberg, H. I. (1997) The transmembrane 7 α-bundle of rhodopsin: distance geometry calculations with hydrogen bonding constraints, Biophys. J. 72, 1963-1985.
49. Pogozheva, I. D., Lomize, A. L., and Mosberg, H. I. (1998) Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints, Biophys. J. 75, 612-634.
50. Munshi, U. M., Pogozheva, I. D., and Menon, K. M. (2003) Highly conserved serine in the third transmembrane helix of the luteinizing hormone/human chorionic gonadotropin receptor regulates receptor activation, Biochemistry 42, 3708-3715.
51. Zhang, P., Johnson, P. S., Zollner, C., Wang, W., Wang, Z., Montes, A. E., Seidleck, B. K., Blaschak, C. J., and Surratt, C. K. (1999) Mutation of human μ opioid receptor, extracellular "disulfide cysteine" residues alters ligand binding but does not prevent receptor targeting to the cell plasma membrane, Brain Res. Mol. Brain Res. 72, 195-204.
52. Yu, H., and Oprian, D. D. (1999) Tertiary interactions between transmembrane segments 3 and 5 near the cytoplasmic side of rhodopsin, Biochemistry 38, 12033-12040.
53. Struthers, M., Yu, H., and Oprian, D. D. (2000) G protein-coupled receptor activation: analysis of a highly constrained, " straitjacketed" rhodopsin, Biochemistry 39, 7938-7942.
54. DeCaillot, F. M., Befort, K., Filliol, D., Yue, S., Walker, P., and Kieffer, B. L. (2003) Opioid receptor random mutagenesis reveals a mechanism for G protein-coupled receptor activation, Nat. Struct. Biol. 10, 629-636.
55. Brooks, B. R., Bruccoleri, E. R., Olafson, E. R., States, D. J., Swaminathan, S., and Karplus, M. (1983) CHARMM: A program for macromolecular energy, minimization and dynamics calculations, J. Comput. Chem. 4, 187-217.
56. Momany, F. A., and Rone, R. (1992) Validation of the general purpose QUANTA3.2/CHARMm force field, J. Comput. Chem. 13, 888-900.
57. Mosberg, H. I., and Fowler, C. B. (2002) Development and validation of opioid ligand-receptor interaction models: the structural basis of μ vs δ selectivity, J. Pept. Res. 60, 329-335.
58. Xu, H., Lu, Y. F., Partilla, J. S., Zheng, Q. X., Wang, J. B., Brine, G. A., Carroll, F. I., Rice, K. C., Chen, K. X., Chi, Z. Q., and Rothman, R. B. (1999) Opioid peptide receptor studies, 11: involvement of Tyr148, Trp318 and His319 of the rat μ-opioid receptor in binding of μ-selective ligands, Synapse 32, 23-28.
59. Bonner, G., Meng, F., and Akil, H. (2000) Selectivity of μ-opioid receptor determined by interfacial residues near third extracellular loop, Eur. J. Pharmacol. 403, 37-44.
60. Ulens, C., Van Boven, M., Daenens, P., and Tytgat, J. (2000) Interaction of p-fluorofentanyl on cloned human opioid receptors and exploration of the role of Trp-318 and His-319 in μ-opioid receptor selectivity, J. Pharmacol. Exp. Ther. 294, 1024-1033.
61. Altenbach, C., Yang, K., Farrens, D. L., Farahbakhsh, Z. T., Khorana, H. G., and Hubbell, W. L. (1996) Structural features and light-dependent changes in the cytoplasmic interhelical E-F loop region of rhodopsin: A site-directed spin-labeling study, Biochemistry 35, 12470-12478.
62. Li, J., Huang, P., Chen, C., de Riel, J. K., Weinstein, H., and Liu-Chen, L. Y. (2001) Constitutive activation of the μ opioid receptor by mutation of D3.49(164), but not D3.32(147): D3.49(164) is critical for stabilization of the inactive form of the receptor and for its expression, Biochemistry 40, 12039-12050.
63. Huang, P., Li, J., Chen, C., Visiers, I., Weinstein, H., and Liu-Chen, L. Y. (2001) Functional role of a conserved motif in TM6 of the rat μ opioid receptor: constitutively active and inactive receptors result from substitutions of Thr6.34(279) with Lys and Asp, Biochemistry 40, 13501-13509.
64. Claude, P. A., Wotta, D. R., Zhang, X. H., Prather, P. L., McGinn, T. M., Erickson, L. J., Loh, H. H., and Law, P. Y. (1996) Mutation of a conserved serine in TM4 of opioid receptors confers full agonistic properties to classical antagonists, Proc. Natl. Acad. Sci. U.S.A. 93, 5715-5719.
65. Befort, K., Zilliox, C., Filliol, D., Yue, S., and Kieffer, B. L. (1999) Constitutive activation of the δ opioid receptor by mutations in transmembrane domains III and VII, J. Biol. Chem. 274, 18574-18581.
66. Kam, K. W., New, D. C., and Wong, Y. H. (2002) Constitutive activation of the opioid receptor-like (ORL1) receptor by mutation of Asn133 to tryptophan in the third transmembrane region, J. Neurochem. 83, 1461-1470.
67. Surratt, C. K., Johnson, P. S., Moriwaki, A., Seidleck, B. K., Blaschak, C. J., Wang, J. B., and Uhl, G. R. (1994) μ opiate receptor. Charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity, J. Biol. Chem. 269, 20548-20553.
68. Mansour, A., Taylor, L. P., Fine, J. L., Thompson, R. C., Hoversten, M. T., Mosberg, H. I., Watson, S. J., and Akil, H. (1997) Key residues defining the μ-opioid receptor binding pocket: a site-directed mutagenesis study, J. Neurochem. 68, 344-353.
69. Spivak, C. E., Beglan, C. L., Seidleck, B. K., Hirshbein, L. D., Blaschak, C. J., Uhl, G. R., and Surratt, C. K. (1997) Naloxone activation of μ-opioid receptors mutated at a histidine residue lining the opioid binding cavity, Mol. Pharmacol. 52, 983-992.
70. Bot, G., Blake, A. D., Li, S., and Reisine, T. (1998) Mutagenesis of a single amino acid in the rat μ-opioid receptor discriminates ligand binding, J. Neurochem. 70, 358-365.
71. Befort, K., Tabbara, L., Bausch, S., Chavkin, C., Evans, C., and Kieffer, B. (1996) The conserved aspartate residue in the third putative transmembrane domain of the δ-opioid receptor is not the anionic counterpart for cationic opiate binding but is a constituent of the receptor binding site, Mol. Pharmacol. 49, 216-223.
72. Befort, K., Tabbara, L., Kling, D., Maigret, B., and Kieffer, B. L. (1996) Role of aromatic transmembrane residues of the δ-opioid receptor in ligand recognition, J. Biol. Chem. 271, 10161-10168.
73. Li, J. G., Chen, C., Yin, J., Rice, K., Zhang, Y., Matecka, D., de Kiel, J. K., DesJarlais, R. L., and Liu-Chen, L. Y. (1999) Asp147 in the third transmembrane helix of the rat μ opioid receptor forms ion-pairing with morphine and naltrexone, Life Sci. 65, 175-185.
74. Mouledous, L., Topham, C. M., Moisand, C., Mollereau, C., and Meunier, J. C. (2000) Functional inactivation of the nociceptin receptor by alanine substitution of glutamine 286 at the C terminus of transmembrane segment VI: evidence from a site-directed mutagenesis study of the ORL1 receptor transmembrane-binding domain, Mol. Pharmacol. 57, 495-502.
75. Shahrestanifar, M., Wang, W. W., and Howells, R. D. (1996) Studies on inhibition of μ and δ opioid receptor binding by dithiothreitol and N-ethylmaleimide. His223 is critical for mu opioid receptor binding and inactivation by N-ethylmaleimide, J. Biol. Chem. 271, 5505-5512.
76. Law, P. Y., Wong, Y. H., and Loh, H. H. (1999) Mutational analysis of the structure and function of opioid receptors, Biopolymers 51, 440-455.
77. Chaturvedi, K., Christoffers, K. H., Singh, K., and Howells, R. D. (2000) Structure and regulation of opioid receptors, Biopolymers 55, 334-346.
78. 3H]β-funaltrexamine covalent binding in the cloned rat μ-opioid receptor, J. Biol. Chem. 271, 21422-21429.
79. Hjorth, S. A., Thirstrup, K., Grandy, D. K., and Schwartz, T. W. (1995) Analysis of selective binding epitopes for the κ-opioid receptor antagonist nor-binaltorphimine, Mol. Pharmacol. 47, 1089-1094.
80. Jones, R. M., Hjorth, S. A., Schwartz, T. W., and Portoghese, P. S. (1998) Mutational evidence for a common κ antagonist binding pocket in the wild-type κ and mutant μ[K303E] opioid receptors, J. Med. Chem. 41, 4911-4914.
81. Larson, D. L., Jones, R. M., Hjorth, S. A., Schwartz, T. W., and Portoghese, P. S. (2000) Binding of norbinaltorphimine (norBNI) congeners to wild-type and mutant μ and κ opioid receptors: molecular recognition loci for the pharmacophore and address components of κ antagonists, J. Med. Chem. 43, 1573-1576.
82. Ballesteros, J. A., Shi, L., and Javitch, J. A. (2001) Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors, Mol. Pharmacol. 60, 1-19.
83. Lomize, A. L., Pogozheva, I. D., and Mosberg, H. I. (1999) Structural organization of G-protein-coupled receptors, J. Comput.-Aided Mol. Des. 13, 325-353.
84. Bondensgaard, K., Ankersen, M., Thogersen, H., Hansen, B. S., Wulff, B. S., and Bywater, R. P. (2004) Recognition of privileged structures by G-protein coupled receptors, J. Med. Chem. 47, 888-899.
85. Schiller, P. W., Weltrowska, G., Nguyen, T. M.-D., Lemieux, C., Chung, N. N., and Lu, Y. (2003) Conversion of δ-, κ- and μ-receptor selective opioid peptide agonists into δ-, κ- and μ-receptor selective antagonists, Life Sci. 73, 691-698.
86. Chabre, M., and Breton, J. (1979) Orientation of aromatic residues in rhodopsin. Rotation of one tryptophan upon the meta I to meta II transition afer illumination, Photochem. Photobiol. 30, 295-299.
87. Baneres, J. L., Martin, A., Hullot, P., Girard, J. P., Rossi, J. C., and Parello, J. (2003) Structure-based analysis of GPCR function: conformational adaptation of both agonist and receptor upon leukotriene B4 binding to recombinant BLT1, J. Mol. Biol. 329, 801-814.
88. Gether, U., Asmar, F., Meinild, A. K., and Rasmussen, S. G. (2002) Structural basis for activation of G-protein-coupled receptors, Pharmacol. Toxicol. 91, 304-312.
89. Gether, U., Ballesteros, J. A., Seifert, R., Sanders-Bush, E., Weinstein, H., and Kobilka, B. K. (1997) Structural instability of a constitutively active G protein-coupled receptor. Agonist-independent activation due to conformational flexibility, J. Biol. Chem. 272, 2587-2590.
90. Abdulaev, N. G., and Ridge, K. D. (1998) Light-induced exposure of the cytoplasmic end of transmembrane helix seven in rhodopsin, Proc. Natl. Acad. Sci. U.S.A. 95, 12854-12859.
91. Choi, G., Landin, J., Galan, J. F., Birge, R. R., Albert, A. D., and Yeagle, P. L. (2002) Structural studies of metarhodopsin II, the activated form of the G-protein coupled receptor, rhodopsin, Biochemistry 41, 7318-7324.
92. Nikiforovich, G. V., and Marshall, G. R. (2003) Three-dimensional model for meta-II rhodopsin, an activated G-protein-coupled receptor, Biochemistry 42, 9110-9120.
93. Ruprecht, J. J., Mielke, T., Vogel, R., Villa, C., and Schertler, G. F. (2004) Electron crystallography reveals the structure of metarhodopsin I, EMBO J. 23, 3609-3620.